Well according to what they said after the raise last year, the plan was that they'd have the money to take Rett through to NDA. I think the comment in the presentation that the toxicity and manufacturing work would carry through to other indications shows that they're trying to cover as many bases as possible with the money they have.
For FXS, we won't know until after the FDA meeting what hoops they need to jump through. I think it's reasonable to assume that Rett will be a good template: another short PhII trial followed by Ph III.
Likewise TBI, until the results come out we don't know how much money they'll need or, indeed, what the process would be. My concern with TBI is not money but time: I'd hate there to be a Ph III trial that lasted for 6 years before the drug got approved.
I would guess that if the TBI trial showed a strong benefit they'd just deploy it. It's the question of what would happen if the benefit was statistically fair to middling.
At this stage I am counting no chickens. But an uneducated guess says that if they need the money for a Ph III FXS trila, they would have partnered/sold out by then.
NEU Price at posting:
12.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)